Floatz logo

ANTI-PSCA MONOCLONAL ANTIBODY AGS-1C4D4

Pancreatic Disease

Agensys, Inc.monoclonal_antibodyPhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Pancreatic Disease cohort.

Asset / SponsorPhaseRating
CEFOXITIN
Memorial Sloan Kettering Cancer Center
Phase 3B
Olaparib
AstraZeneca
Phase 2B
nhs7108
Aimmune Nestlé Health Science US R&D, LLC
Phase 2CCC
Pancrelipase
Aimmune Nestlé Health Science US R&D, LLC
Phase 2CCC
Irinotecan
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2CCC

View all 15 →

Same molecule, other indications

ANTI-PSCA MONOCLONAL ANTIBODY AGS-1C4D4 is also rated in:

pancreatic ductal adenocarcinomaDormant
B
Indicative ·
62 / 100
View asset →
pancreatic neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →
prostate cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →